




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**


LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Maria C. Laccotripe Zacharakis is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Lahive & Cockfield, LLP, to prepare and prosecute patent applications where the patent applicant is the client of Lahive & Cockfield, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Lahive & Cockfield, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Maria C. Laccotripe Zacharakis ceases to lawfully reside in the United States, (ii) Maria C. Laccotripe Zacharakis' employment with Lahive & Cockfield, LLP ceases or is terminated, or (iii) Maria C. Laccotripe Zacharakis ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: August 5, 2003


Harry I. Mbatz
Director of Enrollment and Discipline

Practitioner's Docket No. MP101-020P1RN

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tsai, Fong-Ying, et al.
 Application No.: 10/086,181
 Filed: February 26, 2002
 For: METHODS FOR THE TREATMENT OF METABOLIC DISORDERS,
 INCLUDING OBESITY AND DIABETES

Group No.:

Examiner:

Commissioner for Patents
 Washington, D.C. 20231

**REVOCATION OF PRIOR POWERS OF ATTORNEY
 AND APPOINTMENT OF NEW POWER OF ATTORNEY**

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on June 6, 2002, at Reel 012976, Frame 0200, hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Addressee"
 Mailing Label No. _____

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date:

10/22/02

Maria Laccotripe Zacharakis Ph.D.
 (Type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

RECEIVED

OCT 30 2002

TECH CENTER 1600/2900

Practitioner's Docket No. MPI01-020P1RN

Scott A. Brown, Reg. No. 32,724; Ian R. Silverman, Reg. No. 37,443; Susan M. Perkins, Reg. No. 36,405; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzenko, Reg. No. 38,945; Theodore R. Allen, Reg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 51,609; and Steven A Bossone, Reg. No. 51,196;

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Intellectual Property Group
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139

and direct all telephone calls to Jean M. Silveri at (617) 679-7336.

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Typed Name: Scott A. Brown

Title: Vice President, Chief Patent Counsel

Dated: October 17, 2002